Best Practice & Research Clinical Endocrinology & Metabolism
Volume 23, Issue 6 , Pages 793-800 , December 2009

Drugs that suppress TSH or cause central hypothyroidism

  • Bryan R. Haugen, MD (Professor of Medicine and Pathology)

      Affiliations

    • Corresponding Author InformationTel.: +1 303 724 3921; Fax: +1 303 724 3920.

References 

  1. Surks MI, Sievert R. Drugs and thyroid function. New England Journal of Medicine. 12-21-1995;333(25):1688–1694
  2. de Groot JW, Zonnenberg BA, Plukker JT, et al. Imatinib induces hypothyroidism in patients receiving levothyroxine. Clinical Pharmacology and Therapeutics. 2005;78(4):433–438
  3. Wilber JF, Utiger RD. The effect of glucocorticoids on thyrotropin secretion. Journal of Clinical Investigation. 1969;48(11):2096–2103
  4. Brabant A, Brabant G, Schuermeyer T, et al. The role of glucocorticoids in the regulation of thyrotropin. Acta Endocrinologica. 1989;121(1):95–100
  5. Samuels MH. Effects of variations in physiological cortisol levels on thyrotropin secretion in subjects with adrenal insufficiency: a Clinical Research Center Study. The Journal of Clinical Endocrinology and Metabolism. 2000;85(4):1388–1393
  6. Samuels MH, McDaniel PA. Thyrotropin levels during hydrocortisone infusions that mimic fasting-induced cortisol elevations: a Clinical Research Center Study. The Journal of Clinical Endocrinology and Metabolism. 1997;82(11):3700–3704
  7. Nicoloff JT, Fisher DA, Appleman MD. The role of glucocorticoids in the regulation of thyroid function in man. Journal of Clinical Investigation. 1970;49(10):1922–1929
  8. John CD, Christian HC, Morris JF, et al. Kinase-dependent regulation of the secretion of thyrotrophin and luteinizing hormone by glucocorticoids and annexin 1 peptides. Journal of Neuroendocrinology. 2003;15(10):946–957
  9. Cintra A, Fuxe K, Wikstrom AC, et al. Evidence for Thyrotropin-releasing hormone and glucocorticoid receptor-immunoreactive neurons in various preoptic and hypothalamic nuclei of the male rat. Brain Research. 1-1-1990;506(1):139–144
  10. Alkemade A, Unmehopa UA, Wiersinga WM, et al. Glucocorticoids Decrease thyrotropin-releasing hormone messenger ribonucleic acid expression in the paraventricular nucleus of the human hypothalamus. The Journal of Clinical Endocrinology and Metabolism. 2005;90(1):323–327
  11. Ohzeki T, Hanaki K, Motozumi H, et al. Efficacy of bromocriptine administration for selective pituitary resistance to thyroid hormone. Hormones Research. 1993;39(5–6):229–234
  12. Morley JE. Neuroendocrine control of thyrotropin secretion. Endocrine Reviews. 1981;2(4):396–436
  13. Samuels MH, Henry P, Ridgway EC. Effects of dopamine and somatostatin on pulsatile pituitary glycoprotein secretion. The Journal of Clinical Endocrinology and Metabolism. 1992;74(1):217–222
  14. Kok P, Roelfsema F, Frolich M, et al. Bromocriptine reduces augmented thyrotropin secretion in obese premenopausal women. The Journal of Clinical Endocrinology and Metabolism. 2009;94(4):1176–1181
  15. Lewis BM, Dieguez C, Lewis MD, et al. Dopamine stimulates release of thyrotrophin-releasing hormone from perfused intact rat hypothalamus via hypothalamic D2-receptors. Journal of Endocrinology. 1987;115(3):419–424
  16. ‘t Verlaat JW, Croughs RJ, Hendriks MJ, et al. Bromocriptine treatment of prolactin secreting macroadenomas: a radiological, ophthalmological and endocrinological study. Acta Endocrinologica. 1986;112(4):487–493
  17. Van den Berghe G, de Zegher F, Lauwers P. Dopamine and the sick euthyroid syndrome in critical illness. Clinical Endocrinology. 1994;41(6):731–737
  18. Filippi L, Pezzati M, Cecchi A, et al. Dopamine infusion and anterior pituitary gland function in very low birth weight infants. Biology of the Neonate. 2006;89(4):274–280
  19. Reisine T, Bell GI. Molecular biology of somatostatin receptors. Endocrine Reviews. 1995;16:427–442
  20. Mannavola D, Persani L, Vannucchi G, et al. Different responses to chronic somatostatin analogues in patients with central hyperthyroidism. Clinical Endocrinology. 2005;62(2):176–181
  21. Hofland LJ, Lamberts SW. Somatostatin receptors in pituitary function, diagnosis and therapy. Frontiers of Hormone Research. 2004;32:235–252
  22. Lamberts SW, Zuyderwijk J, den Holder F, et al. Studies on the conditions determining the inhibitory effect of somatostatin on adrenocorticotropin, prolactin and thyrotropin release by cultured rat pituitary cells. Neuroendocrinology. 1989;50(1):44–50
  23. Murray RD, Kim K, Ren SG, et al. The novel somatostatin ligand (SOM230) regulates human and rat anterior pituitary hormone secretion. The Journal of Clinical Endocrinology and Metabolism. 2004;89(6):3027–3032
  24. Lightman SL, Fox P, Dunne MJ. The Effect of SMS 201-995, a long-acting somatostatin analogue, on anterior pituitary function in healthy male volunteers. Scandinavian Journal of Gastroenterology. Supplement. 1986;119:84–95
  25. Hindmarsh PC, Pringle PJ, Stanhope R, et al. The Effect of a continuous infusion of a somatostatin analogue (Octreotide) for two years on growth hormone secretion and height prediction in tall children. Clinical Endocrinology. 1995;42(5):509–515
  26. Kirkegaard C, Norgaard K, Snorgaard O, et al. Effect of one year continuous subcutaneous infusion of a somatostatin analogue, octreotide, on early retinopathy, metabolic control and thyroid function in Type I (insulin-dependent) diabetes mellitus. Acta Endocrinologica. 1990;122(6):766–772
  27. Colao A, Merola B, Ferone D, et al. Acute and chronic effects of octreotide on thyroid axis in growth hormone-secreting and clinically non-functioning pituitary adenomas. European Journal of Endocrinology. 1995;133(2):189–194
  28. Roelfsema F, Frolich M. Pulsatile thyrotropin release and thyroid function in acromegalics before and during subcutaneous octreotide infusion. The Journal of Clinical Endocrinology and Metabolism. 1991;72(1):77–82
  29. Duvic M, Martin AG, Kim Y, et al. Phase 2 and 3 clinical trial of oral bexarotene (targretin capsules) for the treatment of refractory or persistent early-stage cutaneous t-cell lymphoma. Archives of Dermatology. 2001;137(5):581–593
  30. Khuri FR, Rigas JR, Figlin RA, et al. Multi-institutional phase I/II trial of oral bexarotene in combination with cisplatin and vinorelbine in previously untreated patients with advanced non-small-cell lung cancer. Journal of Clinical Oncology. 5-15-2001;19(10):2626–2637
  31. Esteva FJ, Glaspy J, Baidas S, et al. Multicenter phase II study of oral bexarotene for patients with metastatic breast cancer. Journal of Clinical Oncology. 3-15-2003;21(6):999–1006
  32. Cesario RM, Klausing K, Razzaghi H, et al. The rexinoid LG100754 is a novel RXR: PPARgamma agonist and decreases glucose levels in vivo. Molecular Endocrinology. 2001;15(8):1360–1369
  33. Shen Q, Cline GW, Shulman GI, et al. Effects of rexinoids on glucose transport and insulin-mediated signaling in skeletal muscles of diabetic (Db/Db) mice. Journal of Biological & Chemistry. 5-7-2004;279(19):19721–19731
  34. Ogilvie KM, Saladin R, Nagy TR, et al. Activation of the retinoid X receptor suppresses appetite in the rat. Endocrinology. 2004;145(2):565–573
  35. Sherman SI, Gopal J, Haugen BR, et al. Central hypothyroidism associated with retinoid x receptor selective ligands. New England Journal of Medicine. 1999;340:1075–1079
  36. Liu S, Ogilvie KM, Klausing K, et al. Mechanism of selective retinoid x receptor agonist-induced hypothyroidism in the rat. Endocrinology. 2002;143(8):2880–2885
  37. Golden WM, Weber KB, Hernandez TL, et al. Single-dose rexinoid rapidly and specifically suppresses serum thyrotropin in normal subjects. The Journal of Clinical Endocrinology and Metabolism. 2007;92(1):124–130
  38. Sharma V, Hays WR, Wood WM, et al. Effects of rexinoids on thyrotrope function and the hypothalamic–pituitary–thyroid axis. Endocrinology. 2006;147(3):1438–1451
  39. Smit JW, Stokkel MP, Pereira AM, et al. Bexarotene Induced hypothyroidism: bexarotene stimulates the peripheral metabolism of thyroid hormones. The Journal of Clinical Endocrinology and Metabolism. 4-17-2007;
  40. Isojarvi JI, Myllyla VV, Pakarinen AJ. Effects of carbamazepine on pituitary responsiveness to luteinizing hormone-releasing hormone, thyrotropin-releasing hormone, and metoclopramide in epileptic patients. Epilepsia. 1989;30(1):50–56
  41. Miller J, Carney P. Central hypothyroidism with oxcarbazepine therapy. Pediatrics Neurology. 2006;34(3):242–244
  42. Hirfanoglu T, Serdaroglu A, Camurdan O, et al. Thyroid function and volume in epileptic children using carbamazepine, oxcarbazepine and valproate. Pediatrics International. 2007;49(6):822–826
  43. Verrotti A, Basciani F, Morresi S, et al. Thyroid hormones in epileptic children receiving carbamazepine and valproic acid. Pediatrics Neurology. 2001;25(1):43–46
  44. Vigersky RA, Filmore-Nassar A, Glass AR. Thyrotropin suppression by metformin. The Journal of Clinical Endocrinology and Metabolism. 2006;91(1):225–227
  45. Cappelli C, Rotondi M, Pirola I, et al. TSH-lowering effect of metformin in type 2 diabetic patients: differences between euthyroid, untreated hypothyroid and euthyroid on l-t4 therapy patients. Diabetes Care. 6-5-2009;
  46. Isidro ML, Penin MA, Nemina R, et al. Metformin reduces thyrotropin levels in obese, diabetic women with primary hypothyroidism on thyroxine replacement therapy. Endocrine. 2007;32(1):79–82

PII: S1521-690X(09)00083-9

doi: 10.1016/j.beem.2009.08.003

Best Practice & Research Clinical Endocrinology & Metabolism
Volume 23, Issue 6 , Pages 793-800 , December 2009

Article Tools

* Image Usage & Resolution